Date: 28 May 2013

Selecting and Characterizing Drug-Resistant Hepatitis C Virus Replicon

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The current standard of care (SOC) for hepatitis C virus (HCV) genotype 1-infected patients consists of telaprevir or boceprevir in addition to pegylated interferon and ribavirin treatment. Other selective inhibitors of HCV replication are being developed. Drug pressure may, depending on the class of inhibitors, (rapidly) select for drug-resistant variants. Here we describe four different approaches to select in vitro for drug-resistant HCV subgenomic replicons.